logo
  

Sorrento Gets FDA Approval For Phase 1 Study For COVID Treatment; Shares Up 5%

Shares of Sorrento Therapeutics Inc. (SRNE) gained over 5% in extended trading session on Tuesday after the company FDA cleared its Investigational New Drug application for early stage study of STI-2099 in both healthy volunteers and COVID-19 patients.

Sorrento Therapeutics said it received clearance from the FDA for its Investigational New Drug application for its Phase 1 study of the safety and pharmacokinetics of intranasal STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

Sorrento is currently evaluating an intravenous formulation of this potent antibody, STI-2020 (IV), in a Phase 1 study in healthy volunteers and COVID-19 patients with mild symptoms.

"We plan to use our intranasal formulation technology, which allows administering a drug via simple drops in the nose, for other antibodies we are currently developing with a goal of providing coverage against all variants of the SARS-CoV-2 virus that might evade inhibition from treatment with existing therapies," said Dr. Henry Ji, Chairman and CEO of Sorrento.

SRNE closed Tuesday's trading at $9.44, down $0.81 or 7.90%, on the Nasdaq. The stock, however, gained $0.56 or 5.93% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
RELATED NEWS
Follow RTT